Last reviewed · How we verify

IMO-8400 Regimen 2 — Competitive Intelligence Brief

IMO-8400 Regimen 2 (IMO-8400 Regimen 2) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IRAK4 inhibitor. Area: Immunology.

phase 2 IRAK4 inhibitor IRAK4 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

IMO-8400 Regimen 2 (IMO-8400 Regimen 2) — Idera Pharmaceuticals, Inc.. IMO-8400 is a small molecule inhibitor of IRAK4, a key kinase in the Toll-like receptor signaling pathway.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IMO-8400 Regimen 2 TARGET IMO-8400 Regimen 2 Idera Pharmaceuticals, Inc. phase 2 IRAK4 inhibitor IRAK4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IRAK4 inhibitor class)

  1. Idera Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IMO-8400 Regimen 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/imo-8400-regimen-2. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: